Estimate the FN and BMI Levels in Pregnant Women with Pre-Eclampsia
Article Sidebar
Abstract
Preeclampsia, previously known as toxemia, impacts an estimated 4 million people globally and causes the deaths of over 70,000 mothers and 500,000 infants annually. Among all pregnancies, approximately 0.5% are affected by preterm pre-eclampsia, which accounts for 10% of pre-eclampsia cases. Preterm pre-eclampsia is more severe than pregnancies carried to term and linked to increased rates of mother and infant morbidity and death. In this investigation, 100 participants in total were divided into two groups: 50 pregnant women with pre-eclampsia and 50 pregnant women without pre-eclampsia in the control group. The severity of the condition was evaluated by analyzing biomarker FN with BMI of pregnant women. Microsoft Excel 2019 and SPSS software were used to assess the data gathered from August 2024 to December 2025. serum FN level and BMI were increase in patient group compared to the control. Serum FN level is a useful marker to predict and diagnose pre-eclampsia.
Full text article
References
Poon LC, Zaragoza E, Akolekar R, Anagnostopoulos E, Nicolaides KH. Maternal serum placental growth factor (PlGF) in small for gestational age pregnancy at 11(+0) to 13(+6) weeks of gestation. Prenat Diagn 2008; 28(12): 1110–1115.
Chappell LC, Cluver CA, Kingdom J, Tong S. Pre-eclampsia. Lancet. 2021 Jul;398[10297]:341- 354. doi: 10.1016/S0140-6736[20]32335-7.
Phipps, E. A., Thadhani, R., Benzing, T., & Karumanchi, S. A. (2019). Pre-eclampsia: pathogenesis, novel diagnostics and therapies. Nature reviews. Nephrology, 15(5), 275–289.
Dimitriadis E, Rolnik DL, Zhou W, EstradaGutierrez G, Koga K, Francisco RPV, et al. Pre-eclampsia. Nat Rev Dis Primers. 2023 Feb 16; 9[1]:8.
WHO recommendation: Calcium supplementation during pregnancy for the prevention of pre-eclampsia and its complications. Geneva: World Health Organization; 2018. PMID: 30629391 .
Magee, L. A. et al. The 2021 International Society for the Study of Hypertension in Pregnancy classification, diagnosis & management recommendations for international practice. Pregnancy Hypertens. 27, 148–169 (2022).
Mol, B. W. J., Roberts, C. T., Thangaratinam, S., Magee, L. A., De Groot, C. J. M., & Hofmeyr, G. J. (2016). Pre-eclampsia. The Lancet, 387(10022), 999–1011.
Braunthal, S., & Brateanu, A. (2019). Hypertension in pregnancy : Pathophysiology and treatment. https://doi.org/10.1177/2050312119843700
Oparil, S., Zaman, M. A., & Calhoun, D. A. (2003). Pathogenesis of Hypertension. Annals of Internal Medicine, 139(9), 761–776.
Townsend R, O’Brien P, Khalil A. Current best practice in the management of hypertensive disorders in pregnancy. Integrated blood pressure control. 2016;9: 79–94.
Tarca, A. L., Romero, R., Benshalom-Tirosh, N., Than, N. G., Gudicha, D. W., Done, B., Pacora, P., Chaiworapongsa, T., Panaitescu, B., Tirosh, D., Gomez-Lopez, N., Draghici, S., Hassan, S. S., & Erez, O. (2019). The prediction of early preeclampsia: Results from a longitudinal proteomics study. In PLoS ONE (Vol. 14, Issue 6).
Fondjo, L. A., Boamah, V. E., Fierti, A., Gyesi, D., & Owiredu, E. W. (2019). Knowledge of preeclampsia and its associated factors among pregnant women: A possible link to reduce related adverse outcomes. BMC Pregnancy and Childbirth, 19(1), 1–7.
Wilkinson J, Cole G. Preeclampsia knowledge among women in Utah. Hypertens Pregnancy. 2018 Feb;37(1):18-24. doi: 10.1080/10641955.2017.1397691. Epub 2017 Nov 15. PMID: 29140734.
Authors
This work is licensed under a Creative Commons Attribution 4.0 International License.